Rating Apathy in Huntington’s Disease: Patients and Companions Agree

Sarah Mason1, Roger A Barker

  • 1John Van Geest Centre for Brain Repair, University of Cambridge, Cambridge, UK. slm64@cam.ac.uk

Insights

Self-rated apathy scores in Huntington's disease (HD) align with companion ratings and remain stable over 18 months. This validates patient self-assessment for apathy in HD research and clinical practice.

Area of Science:

  • Neurodegenerative diseases
  • Neurology
  • Psychiatry

Background:

  • Apathy is a prevalent symptom in Huntington's disease (HD), manifesting even in early stages.
  • Patients with HD often lack self-awareness regarding their apathy, necessitating reliance on clinician or companion assessments.
  • The longitudinal progression of apathy in HD has not been clearly defined.

Purpose of the Study:

  • To assess the concordance between self-reported apathy and companion-reported apathy in Huntington's disease patients.
  • To investigate the clinical correlations of apathy with motor, cognitive, and functional status.
  • To examine the stability of apathy over an 18-month period in HD patients.

Main Methods:

  • Apathy was evaluated using the Apathy Evaluation Scale in a cross-sectional cohort of 106 HD patients (early to late stage).
  • A subgroup of 62 patients was followed longitudinally over approximately 18.7 months.
  • Comparisons were made between self- and companion-rated apathy scores, alongside analyses of clinical correlates.

Main Results:

  • A high correlation was observed between self-rated and companion-rated apathy scores in the cross-sectional analysis.
  • Both self- and companion-rated apathy showed associations with motor and functional impairments, with a complex relationship to cognition.
  • Longitudinal data indicated that apathy levels remained stable over the 18-month follow-up period.

Conclusions:

  • Apathy in Huntington's disease can be reliably assessed by both patients and their companions.
  • Apathy scores demonstrate significant stability over an 18-month timeframe in HD patients.
  • These findings support the use of self-rated apathy in research and clinical settings and inform the design of therapeutic intervention studies.
Abstract

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.4K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K